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The newborn’s immune system must transition from a sterile haploidentical uterus to the 
world full of antigens. Regulatory B-cells (Breg; broadly defined as CD19+CD24hiCD38hi) 
are tolerance promoters in the adult immune system. They can inhibit IFN-γ and IL-17 
production by T-cells and are essential in different conditions, including pregnancy. Breg 
have still not been well characterized in umbilical cord blood, where we hypothesize that 
they are pivotal in the achievement of tolerance. We studied CD19+CD24hiCD38hi Breg in 
healthy umbilical cord blood (hUCB) compared to healthy peripheral adult blood (hAPB). 
Total numbers of Breg were increased in hUCB compared to hAPB (34.39 vs. 9.49%; 
p = 0.0002), especially in the marginal zone-like B-cell subset, in which the most marked 
difference could be observed between hUCB and hAPB (60.80 vs. 4.94%; p = 0.1). 
CD24hiCD38hi subset in hUCB produced IL-10 and inhibited T-cell IFN-γ [1.63 vs. 0.95 
stimulation ratio (SR); p =  0.004] and IL-4 (1.63 vs. 1.44 SR; p =  0.39) production. 
Phenotypically, hUCB Breg cells presented IgMhiIgDhiCD5+CD10+CD27− markers, similar 
to those described in hAPB Breg cells, but they showed increased IgM concentration 
and decreased expression of CD22 and CD73 markers. Our work characterized the 
frequency, phenotype, and function of Breg in hUCB, which may contribute to under-
standing of immune tolerance during pregnancy, paving the way to a new approach to 
immune-related diseases in the fetus and the newborn.
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inTrODUcTiOn
Avoidance of unwanted immune responses through peripheral tolerance involves several regula-
tory/suppressor molecules and cell types. Regulatory B (Breg)-cells are a rare B-cell subpopulation 
with this regulatory/suppressor function. Several markers have been described for the detection 
and sorting of these cells. This is nicely reviewed by Rosser and Mauri (1). Breg cells are known 
Abbreviations: BFA, brefeldin A; Breg, B regulatory cell; FCS, fetal calf serum; hAPB, human adult peripheral blood; hUCB, 
human umbilical cord blood; ICS, intracellular cytokine staining; NoBreg, non-regulatory B-cell; PIM, PMA–ionomycin– 
monensin; RT, room temperature; SR, stimulation ratio; Th, T helper cell; Treg, T regulatory cell.
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to perform their suppressive action by IL-10/TGF-β production, 
cell-to-cell contact by CD80/86 interaction with T-cells, and 
CD73-dependent adenosine production (1–6). CD24hiCD38hi 
and CD24hiCD27+ have been used recently for the study of Bregs 
in pregnant women (7).
The most studied subset of Breg cells is defined by CD24hi 
and CD38hi expression in B-cells (2, 6, 8). Phenotypically, these 
cells also express IgM, IgD, CD5, CD10, and CD1d (2), resem-
bling transitional B-cells (9). Breg cells are mainly defined by 
their regulatory function: Mauri et  al. demonstrated that the 
CD19+CD24hiCD38hi subset is enriched in IL-10 production 
and can inhibit IFN-γ production (2, 10) and block T helper-cell 
(Th)1 and Th17 differentiation while maintaining T regulatory 
(Treg) cell population (6). Their implication in human immune-
related diseases has been studied mostly in autoimmune (11) and 
allergic diseases (12, 13), persistent infections such as HIV (14), 
HBV (15), and Mycobacterium tuberculosis (16), cancer (17), 
transplantation and, as demonstrated recently, pregnancy (7, 12, 
18–20).
Regulatory B-cells are an important player in the achievement 
of the tolerogenic immune state of the mother to its haploidenti-
cal fetus during pregnancy. Maternal–fetal tolerance is achieved 
through different mechanisms such as an increase of Treg cells, 
expression of CD274 (PD-L1) in the trophoblastic tissue, and an 
increase of Breg cells (21, 22). Early pregnancy factor enhances 
Treg-cell production and IL-10 and TGF-β expression in spleno-
cytes from female mice (23). In pregnant mice, the increase in 
Breg is necessary to avoid immunological abortion. In fact, the 
transfer of Breg cells to abortion-prone mice leads to a Treg-cell 
increase and maintains dendritic cells in an immature state, pro-
moting fetal–maternal tolerance (19). In humans, B-cells increase 
IL-10 production in response to human gonadotropic hormone 
from pregnant woman serum (18). Also, there is an increase of 
Breg during the first trimester of pregnancy that does not occur 
in women with spontaneous abortion (18). Moreover, women 
treated with rituximab, a B-cell-depleting antibody, during preg-
nancy presented a higher rate of first-trimester pregnancy loss 
(24). The role of B cells during pregnancy changes in its various 
stages. A decrease in CD24hiCD38hi B cells in the third trimester 
of pregnancy has been described recently (7), as lower levels of 
IL-10 in pregnant women (25). Furthermore, there are lower 
BAFF levels in pregnant women suffering from preeclampsia in 
comparison with healthy ones; BAFF levels are higher in healthy 
umbilical cord blood (hUCB) than in the pregnant mother at 
the time of delivery (26). These data highlight the importance of 
B-cells, specifically Breg, in the mother’s achievement of immune 
tolerance during the first stages of pregnancy.
B-cell development and maturation is a complex and regulated 
process. In peripheral blood, we can encounter different B cell 
subsets that include naïve, transitional, marginal zone-like B-cells 
[expressing IgM, IgD, and CD27 in their membrane (27, 28)], 
mature B-cells, and plasmablasts (27, 29).
B-cells have been thought to be mere antibody factories for 
years, but it is now known that they have different functions that 
include cytokine production and regulation of T-cell responses. 
Activation status of B-cells has been studied. CD25 expression 
in B-cells is related with better antigen presentation, more 
proliferation, and an increased response to IL-2 (30). Another 
B-cell activation marker is CD71, the transferrin receptor. CD71 
regulates the iron uptake of activated B-cells (31). Activation 
of B-cells is tightly modulated. CD22 is a B-cell-restricted 
molecule that downregulates the signal between CD19 and the 
BCR (32–34). The lack of this regulatory molecule provokes an 
increase in B10 cells in mice (35).
Along with an important anti-infection role, the immune 
system of the fetus must also tolerate its haploidentical mother 
as well as harmless antigens after delivery. To reduce the risk of 
alloimmune reactions between mother and fetus, APCs from the 
newborn selectively impair production of Th1-related cytokines 
(36). Although vaginal or cesarean delivery can affect leukocyte 
populations and plasma concentration of some cytokines (37), 
hUCB T-cells presented lower IFN-γ production after mitogen 
stimulation independently of the way of delivery (38). This 
regulation is partially explained by impaired IL-12 production 
caused by a defect in nucleosome remodeling and the repression 
of IL-12p35 at the chromatin level. Also, murine CD5+ B-cells 
in neonates have been described as contributing to the reduced 
production of IL-12 by APCs through IL-10 production in 
response to TLR9 stimulation (39). Recently, it was described how 
asthmatic mothers of infants with early allergy had an increase 
in transitional B-cells in the late-pregnancy period, suggesting 
that these cells may play a role in the Th1/Th2 bias observed in 
neonates (20). Furthermore, it is known that infusion of stem cells 
from hUCB rather than adult bone marrow enables transplanta-
tion in patients with increased donor–recipient HLA mismatch 
(40). Recently, it was shown that B-cell-mediated regulation 
was one of the possible mechanisms explaining this augmented 
allogenic tolerance (41).
Human Breg cells in umbilical cord blood and their implica-
tions in the achievement of tolerance are not fully characterized. 
This work is an attempt to further characterize the Breg cell 
population in cord blood of healthy neonates. We observed an 
increased number of CD19+CD24hiCD38hi B-cells, especially 
among marginal zone-like B-cells, phenotypically comparable 
to adult Breg but with particular differences and functionally 
inhibiting IFN-γ and IL-4 production.
MaTerials anD MeThODs
Blood extraction
Eight healthy pregnant women with uneventful pregnancies and 
eight anonymous adult healthy controls [three males and five non-
pregnant females; median age, 25.5 years (range, 21–50 years)] 
were enrolled in this study over a period of 2 months. hUCB from 
the enrolled pregnant women was drawn at the time of delivery. 
A total volume of 20 ml was drawn from each subject or from the 
hUCB into lithium-heparinized and EDTA-treated tubes.
This study was carried out in accordance with the recom-
mendations of Ley General de Sanidad (25/4/1986) Art. 10 with 
written informed consent from all subjects. All subjects gave 
written informed consent in accordance with the Declaration of 
Helsinki. The protocol was approved by the ethics committee of 
the Hospital Sant Joan de Déu (number of the Comité Ético de 
Investigaciones Clínicas: PIC-50-12).
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Peripheral Blood Mononuclear cells 
(PBMcs) isolation, sorting, and culture
Peripheral blood mononuclear cells from hUCB and healthy 
controls were isolated with Ficoll-Hipaque (Sigma-Aldrich, St. 
Louis, MO, USA) density gradient centrifugation of heparin-
ized blood. Cells were subsequently washed three times with 
PBS 1× (Roche Diagnostics, Barcelona, Spain) and cultured 
with complete medium [RPMI (Gibco, Grand Island, NY, USA) 
supplemented with 10% heat-inactivated fetal calf serum (FCS; 
Sigma-Aldrich, St. Louis, MO, USA), 1  μg/ml penicillin, and 
1  μg/ml streptomycin (Invitrogen, Grand Island, NY, USA)]. 
Viable cells were counted using a hemocytometer in an inverted 
microscope.
We explored the regulatory function of hUCB B-cells by 
studying CD3−CD19+CD24hiCD38hi cell subset because although 
it is a heterogeneous population, most Breg cells lie in this com-
partment. For Th1/Th2/Th17 evaluation, coculture assays were 
performed in sorted PBMCs isolated from hUCB: hUCB PBMCs 
were sorted using the FACS-ARIA II sorter (BD Bioscience, San 
Jose, CA, USA). Cell populations were defined as Breg: CD3–
CD19+CD24hiCD38hi, NoBreg: CD3–CD19+CD24intCD38int (2), 
and T-cells: CD3+CD19–CD25−. These hUCB sorted cells were 
cocultured in a CD3 pretreated plate (24 h, 4°C, 0.5 μg/ml, clone 
33-2A3 developed in HCB by Dr. R. Vilella) in three different 
conditions: T-cells only, T-cells and Breg at 1:1 ratio, and T-cells 
and NoBreg cells at 1:1 ratio. After 72 h of coculture, cells were 
stimulated for 5 h with PMA–ionomycin–monensin [PIM; PMA 
50  ng/ml (Sigma-Aldrich, St. Louis, MO, USA) +  ionomycin 
1 μl/ml (Sigma-Aldrich, St. Louis, MO, USA) in the presence of 
monensin (GolgiStop from Th1/Th2/Th17 phenotyping kit, 4 μl 
for 6 ml of culture)] or left with monensin alone to stop cytokine 
secretion in the Golgi compartment. Cells were stained for flow 
cytometry.
For IL-10 detection in the supernatant of B-cell cultures, we 
performed positive magnetic separation of CD19+ cells (>98% 
purity). After separation, 400,000 B-cells were cultured in a 
96-well plate with or without CD40L (1 μg/ml) and CpG-B (1 μg/
ml). After 48 h, 100 μl of supernatant were removed and analyzed 
by Luminex following manufacturer’s instructions. Cells were 
cultured for 5 more hours in the presence of brefeldin A (BFA) 
alone or LPS/PMA/ionomycin and BFA. Intracellular cytokine 
staining (ICS) for IL-10 detection was then performed.
Flow cytometry
For the immunophenotype, cell staining was performed in 
50 μl EDTA whole blood. For surface staining, whole blood 
was incubated for 15 min at room temperature (RT) with the 
surface antigen antibodies at proper concentration. To lyse 
and fix cells, cells were incubated with 2 ml of BD FACS lysing 
solution 1× (BD bioscience, San Jose, CA, USA) for 15  min 
at RT. Cells were then washed two times with FACS buffer 
(phosphate-buffered saline with 5% FCS, 0.5% BSA, and 0.07% 
NaN3) and acquired using a FACSCanto-II (BD Bioscience) 
cytometer.
T regulatory intracellular staining was performed with Treg 
Detection Kit (CD4/CD25/FoxP3) (Milteny Biotec, Germany) 
following the manufacturer’s instructions. Briefly, surface stain-
ing was performed as described above, and then cells were fixed 
with 500 μl of fixation buffer for 30 min at 4°C. Cells were washed 
two times with FACS buffer and a third time with Perm Buffer. 
To perform the blocking, cells were incubated with 20 μl of Perm 
Buffer and 5 μl of FcR Blocking Reagent for 5 min at RT. Cells 
were then stained with FoxP3-APC antibody for 30 min at 4°C. 
Finally, cells were washed with FACS buffer and acquired with 
the cytometer.
For detection of IL-10 production, as previously reported 
(21), cells were matured 48  h with CD40L (1  μg/ml; Insight 
genomics, Falls Church, VA, USA) and ODN-2006 Cp (USA), 
PMA (50 ng/mL), and ionomycin (1 μl/ml) in the presence of 
BFA (10 μl/ml, Sigma-Aldrich, St. Louis, MO, USA). For detec-
tion of spontaneous IL-10 production, cells were incubated for 
5 h in the presence of BFA to stop cytokine secretion via Golgi 
transport and then washed with FACS Buffer and incubated 
with mAb anti-human surface molecules for 15 min at RT; cells 
were then permeabilized following “Th1, Th2, Th17 phenotyping 
kit®” (BD Bioscience, San Jose, CA, USA) protocol described 
below and incubated for 30 min at RT, dark with anti-IL-10 Ab. 
Cells were then washed with FACS buffer and acquired with the 
cytometer.
Intracellular Cytokine Staining for IFN-γ, IL-4, and IL-17 was 
performed following the “Th1, Th2, Th17 phenotyping kit®” (BD 
Bioscience, San Jose, CA, USA) protocol. Briefly, cells were first 
washed with FACS buffer and then fixed incubating with 600 μl 
of Cytofix buffer for 10 min at RT and washed twice with FACS 
buffer. To permeabilize them, the membrane cells were incubated 
with 600 μl of Perm/Wash for 15 min at RT and then incubated 
for 45 min with the corresponding surface and intracellular anti-
bodies. Cells were then washed with FACS buffer and acquired 
with the cytometer.
Panels of direct fluorochrome-conjugated anti-human anti-
bodies were used with the following antibodies: CD3-APCCy7, 
CD3-AlexaFluor750, CD4-FITC, CD4-PerCPCy5.5, CD5-APC, 
CD8-PerCPCy5.5, CD10-APCH7, CD16-PE, CD19-PECy7, 
CD19-APCCy7, CD19-BV510, CD21-FITC, CD21-PECy5.5, 
CD22 BV421, CD24-PerCPCy5.5, CD25-PE, CD25-APCH7, 
CD27-PECy7, CD38-APC, CD38-PECy7, CD45-APC, CD45-
PECy7, CD56-PE, CD71-APC, CD73-BV421, CD86-FITC, 
CD127-PECy7, IFN-γ-FITC, IgD-PE, IgD-FITC, IgM-FITC, 
IgM-BV421, IL-4-APC, IL-10-PE, IL-17-PE, PD-L1-APC, 
TCRab-FITC, and TCRgd-PE. See Table 1 for panel and antibod-
ies details.
Cells were acquired on a FACS CANTO II flow cytometer 
(BD Bioscience, San Jose, CA, USA) within the next 2 h after cell 
staining. Data analysis was performed using FlowJo 7.3 software 
(TreeStar, Inc., Ashland, OR, USA). Absolute number of lympho-
cytes was determined with a hematological cell counter.
statistical analysis
Statistical analysis was performed using Prism 6 software 
(GraphPad, La Jolla, CA, USA) and Microsoft Excel (2010). As 
the cohort did not show normal distribution, we performed 
Mann–Whitney test for all conditions. Differences between 
values were considered statistically significant when p < 0.05.
TaBle 1 | antibody panels used for umbilical cord and adult peripheral blood phenotyping.
Panel antibody specificity–fluorochrome-clone
T–B–NK phenotype CD3a CD4b CD8a CD16/CD56 CD19a CD45a
APCCy7 FITC PerCPCy5.5 PE PECy7 APC
SK7 VIT4 RPA-T8 B73/MY31 HIB19 2D1
T-subphenotype CD3a CD8a CD45RAa CD45ROa TCRaba TCRgda
APCCy7 PerCPCy5.5 PECy7 APC FITC PE
SK7 RPA-T8 L48 UCHL1 WT31 11F2
B-subphenotype-1 CD19a CD21a CD38a IgDa IgMc
PECy7 PECy5 APC PE FITC
SJ25C1 B-ly4 HIT2 IA6-2 SA-DA4
B-subphenotype-2 CD19a CD27c CD38a IgDa IgMc
PECy7 PECy7 APC PE FITC
SJ25C1 1A4CD27 HIT2 IA6-2 SA-DA4
Regulatory T-cells CD3c CD4b CD25b CD127a
AlexaFluor750 FITC PE PECy7
UCHT1 VIT4 4E3 HIL-7R-M221
Regulatory B-cells CD19a CD24a CD38a
PECy7 PerCPCy5.5 APC
SJ25C1 ML5 HIT2
Breg sorting CD3c CD19a CD25b CD24a CD38a
FITC PECy7 PE PerCPCy5.5 APC
UCHT1 HIB19 4E3 ML5 HIT2
IL-10 intracellular cytokine 
staining
CD19a IL-10a
PECy7 PE
HIB19 JES3-9D7
Th1/tTh2/Th17 phenotyping kit CD3a CD4a IFNga IL4a IL17a
APCCy7 PerCPCy5.5 FITC APC PE
SK7 SK3 B27 MP4-25D2 N49-653
Breg panel 1 CD19a CD24a CD38a CD27c IgMa IgDc
APCCy7 PerCPCy5.5 APC PECy7 BV421 FITC
SJ25C1 ML5 HIT2 1A4CD27 G20-127 IADB6
Breg panel 2 CD19a CD24a CD38a CD25a CD73a CD71d
BV510 PerCPCy5.5 PECy7 APCH7 BV421 APC
SJ25C1 ML5 HB7 M-A251 AD2 HI166
Breg panel 3 CD19a CD24a CD38a CD21a CD5c CD10e
BV510 PerCPCy5.5 PECy7 FITC APC APCH7
SJ25C1 ML5 HB7 B-Ly4 BL1a HI10a
Breg panel 4 CD19a CD24a CD38a PD-L1e CD22e CD86d
APCCy7 PerCPCy5.5 PECy7 APC BV421 FITC
SJ25C1 ML5 HB7 29E-2A3 S-HCL-1 BU63
aBD Biosciences.
bMilteny Biotech.
cBeckman Coulter (Brea, CA, USA).
dImmunotools (Friesoythe, Germany).
eBiolegend (San Diego, CA, USA).
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resUlTs
Description of reference Values of 
leukocyte and lymphocyte subsets in 
hUcB
We first analyzed monocyte, neutrophil, and lymphocyte subset 
frequency. For lymphocyte subset study, we based our panels 
on and used the reference values of clinical guide references 
(27, 42–44). Values observed were within-reported refer-
ence values (27, 42, 43, 45, 46). We encountered, as expected, 
significant differences between healthy adult peripheral blood 
[healthy peripheral adult blood (hAPB), n  =  5] and hUCB 
(n = 6). Specifically, we observed more naïve T-cell compartment 
(CD45RA+CD45RO−, 46.9 vs. 24.18% of T-cells, p  =  0.004). 
B-cells were also enriched in the more immature subsets. There 
was an increase in IgD/IgM double-positive B-cells (92 vs. 62.28% 
of B-cells, p = 0.002), marginal zone-like B-cells (CD19+IgM+Ig
AB
FigUre 1 | hUcB is enriched in Breg population when compared with 
haPB. (a) Breg gating strategy and representative example of hAPB/hUCB 
Breg and NoBreg cells. (B) Frequency of B-cells and Breg cells among 
B-cells in hAPB (n = 8) and hUCB (n = 8). hUCB, human umbilical cord 
blood; hAPB, human adult peripheral blood; Breg, B regulatory cell; NoBreg, 
non-regulatory B-cell. ***p < 0.001.
TaBle 2 | evaluation of different leukocyte and lymphocyte populations 
and subpopulations in hUcB vs haPB.
Population hUcB haPB p
Mean seM Mean seM
% of leukocytes
Monocytes 7.54 1.39 5.77 1.25 0.02
Lymphocytes 29.63 7.19 22.42 4.69 0.11
Neutrophils 41.31 9.47 52.28 8.19 0.04
% of lymphocytes
T lymphs 65.96 4.33 74.88 1.79 0.22
B lymphs 17.81 2.03 13.76 1.36 0.23
NK cells 13.80 3.20 9.47 2.19 0.41
NKT-cells 1.62 0.23 6.16 1.15 0.002
CD3+CD4+ 46.70 3.47 45.54 2.50 0.62
CD3+CD8+ 17.21 1.44 23.56 1.79 0.03
CD3+CD4/8− 1.30 0.15 5.11 1.13 0.01
% of T-cells
TCRαβ 93.85 0.4822 89.3 1.202 0.009
TCRγd 1.90 0.3044 7.32 1.976 0.03
CD45RA+CD45RO− 46.9 2.321 24.18 5.006 0.004
CD8+CD45RA+CD45RO− 16.2 1.236 10.71 2.866 0.25
CD8−CD45RA+CD45RO− 30.73 2.333 13.45 2.866 0.009
CD45RO+ 52.65 2.301 75.72 5.035 0.004
CD8+CD45RO+ 9.765 1.174 19.14 2.185 0.004
CD8−CD45RO+ 42.9 1.784 56.51 4.081 0.004
CD45RA+CD45RO+ 44.87 2.091 37.94 5.966 0.66
CD8+CD45RA+CD45RO+ 10 1.147 17.79 1.95 0.004
CD8−CD45RA+CD45RO+ 35.18 1.895 20.1 4.82 0.02
CD45RA−CD45RO− 8.048 0.7985 37.78 2.205 0.004
CD8+CD45RA−CD45RO− 0.1217 0.03497 1.35 0.3404 0.004
CD8−CD45RA−CD45RO− 7.923 0.7755 36.41 2.145 0.004
Treg cells 0.52 0.13 0.23 0.08 0.13
% of B-cells
IgD+IgM+ 92 1.304 62.28 4.617 0.002
Marginal zone-like B-cells 40.74 2.464 17.29 3.669 0.002
Naïve B-cells 47.7 3.487 4.046 0.7584 0.002
Transitional B-cells 54 4.88 18.78 2.761 0.002
IgD+IgM− 3.638 1.649 14 2.875 0.006
IgD−IgM− 3.903 0.5775 1.639 0.3791 0.003
Switched memory B-cells 2.574 0.5774 63.8 5.043 0.002
IgD−IgM+ 0.4338 0.08744 3.603 0.7951 0.0003
CD38lowCD21low B-cells 0.0475 0.02541 2.377 0.5152 0.0003
Plasmablasts 1.391 0.2774 3.92 0.8957 0.02
hUCB, human umbilical cord blood; hAPB, human adult peripheral blood; p, 
significance value; marginal zone-like B-cells, CD19+IgM+IgD+CD27+; switched memory 
B-cells, CD19+IgM−IgD−CD27+; naïve B-cells, CD19+IgD+CD27−; transitional B-cells, 
CD19+IgMhiCD38hi; plasmablasts, CD19+IgM+CD38low.
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D+CD27+; 40.74 vs. 17.29% of B-cells, p = 0.002), naïve B-cells 
(CD19+IgD+CD27−; 47.7 vs. 17.4% of B-cells; p = 0.0002), and 
transitional B-cells (CD19+CD38+IgMhi; 54 vs. 18.78% of B-cells, 
p = 0.006) (Table 1; Table 2; Figure S1 in Supplementary Material).
Breg cells are Present at higher 
Frequency in hUcB than in haPB
There was an increased frequency of Breg cells among total 
CD19+CD24hiCD38hi B-cells in hUCB (34.39%  ±  2.49 of 
B-cells in hUCB, 9.49 ± 1.27% of B-cells in hAPB; mean ± SD; 
p =  0.0002) (Figure  1). After evaluating the presence of Breg 
cells among total B-cells, we studied Breg cells in different 
B-cell subsets (Figures  2A,B) in both hUCB and hAPB. 
Studied B-cell subsets were defined as (i) CD19+IgM+IgD+, 
(ii) CD19+IgM−IgD+, (iii) naïve cells (CD19+IgD+CD27−), (iv) 
marginal zone-like cells (CD19+IgD+CD27+), and (v) class-
switched cells (CD19+IgM−IgD−). In both hUCB and hAPB, 
CD19+CD24hiCD38hi Breg cells were present in all the above-
described B-cell subsets. Nevertheless, the marginal zone-like 
B-cell subset was the most enriched in Breg and showed the most 
marked difference between hUCB and hAPB (60.8 vs. 4.94%; 
p = 0.1), compared to the other subsets: naïve subset (30.58 vs. 
3.26%; p = 0.1), IgD+IgM+ B-cells (30.76 vs. 3.39%; p = 0.057), 
IgD+IgM− B-cells (6.02 vs. 0.51% of B-cells; p = 0.057), and class-
switched B-cells (10.8 vs. 0.49% of B-cells; p = 0.1) (Figure 2C).
il-10 Production at Baseline is increased 
in hUcB compared with haPB, in Both 
Breg and non-Breg compartments
Human Breg cannot be defined solely based on a phenotype 
composed of conventional B-cell markers. Analyses of Breg 
functionality are necessary to confirm the regulatory function of 
this population. The capacity to produce IL-10 is an important 
functional item that defines CD19+CD24hiCD38hi Breg cells (2–4), 
although it is not unique to this cell type (47, 48). We observed 
AB
C
FigUre 2 | Breg frequency is significantly higher in hUcB than in haPB among marginal zone-like, naïve, and igD+igM+ cells. (a) Gating strategy and 
representative hUCB example. (B) Representative hAPB example. (c) Breg percentage in different B-cell populations in hUCB (n = 3) and hAPB (n = 4). hUCB, 
human umbilical cord blood; hAPB, human adult peripheral blood; Breg, regulatory B-cell; NoBreg, non-regulatory B-cell; MZ, marginal zone-like. *p < 0.05.
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that hUCB B-cells produced spontaneously (by incubating cells 
for 5 h in the presence of BFA) higher levels of IL-10 than hAPB, 
but this difference was no longer observed after stimulation 
(Figure  3; Figure S3 in Supplementary Material). When we 
analyzed the different B-cell subsets, we observed that both Breg 
and NoBreg [defined as CD19+CD24intCD38int (2)] from hUCB 
showed a tendency toward a spontaneously higher IL-10 produc-
tion than hAPB (3.93 vs. 2.29%; p = 0.2 for B-cells; 5.54 vs. 1.92%; 
AB C
FigUre 3 | Breg cells from hUcB can produce il-10 after stimulation and spontaneously. (a) Intracellular IL-10 staining in one representative hUCB 
example in CD40L + CPG maturation + CLIP-B stimulation condition. (B) IL-10 intracellular staining at 48 h of maturation with CD40L plus GPG followed by 
non-stimulation or stimulation with CLIP-B in hUCB (n = 4) and healthy peripheral adult blood (hAPB) (n = 4). (c) B, Breg, and NoBreg cells spontaneous production 
of IL-10 after 5 h incubation in the presence of BFA B in hUCB (n = 3) and hAPB (n = 3). CLIP-B, CpG, LPS, PMA, and ionomycin after 5 h in the presence of BFA; 
BFA, brefeldin A; hAPB, human adult peripheral blood; hUCB, human umbilical cord blood; Breg, regulatory B-cells; NoBreg, non-regulatory B-cell. **p < 0.01.
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p = 0.1 for Breg and 6.15 vs. 1.35%, p = 0.1 for NoBreg; Figure 3; 
Table SII in Supplementary Material), suggesting an important 
role for IL-10 from B-cells in hUCB.
hUcB Breg inhibit iFn-γ and il-4 
Production by T-cells When cocultured
To corroborate the suppressive capacity of phenotypically 
described hUCB Breg, we performed T:Breg and T:NoBreg 
coculture assays in hUCB sorted PBMCs. We analyzed IFN-γ, 
IL-4, and IL-17 production by T-cells after 72 h coculture in the 
presence of plate-bound CD3 with or without hUCB Breg (as 
defined by CD19+CD24hiCD38hi) or NoBreg cells (as defined by 
CD19+CD24intCD38int), with PMA–ionomycin in the presence of 
monensin during the previous 5  h. We observed a statistically 
significant inhibition of IFN-γ stimulation ratio (SR) by T-cells 
when cocultured with Breg cells [1.63 vs. 0.95 SR; p = 0.004]. This 
was not observed when cocultured with NoBreg cells (1.63 vs. 
1.44 SR; p = 0.39). For IL-4, we observed a significant decrease in 
the SR in the T-cell-Breg coculture condition in comparison with 
T-cells alone (1.66 vs. 0.86 SR; p = 0.02) and T-cells:NoBreg (0.86 
vs. 1.79 SR; p = 0.009). We cannot state the effect of Breg cells in 
the IL-17 production as we cannot clearly detect its production 
after PIM stimulation (Figure  4; Table SIII in Supplementary 
Material). These data demonstrated that hUCB Breg cells play 
a regulatory function by inhibiting IFN-γ production by T-cells 
when cocultured.
hUcB Breg show Phenotypical 
Differences with haPB-Described Breg
In concordance with the reported phenotype (2), hAPB Breg 
were IgMhiIgDhiCD5+CD10+CD27low. hUCB Breg presented 
a similar phenotype but with some differences: hUCB Breg 
showed more IgM per cell [mean fluorescence intensity (MFI); 
13,380 vs. 7,716; p  =  0.057] and a diminished frequency of 
CD27+ cells (0.65 vs. 6.11%; p = 0.057). hUCB Breg were then 
IgMhi+IgDhiCD5+CD10+CD27−. This difference in IgM and CD27 
expression was extendable to, but less marked in, NoBreg cell 
compartment. Concretely, NoBreg cells in hUCB presented a 
IgM+IgD+CD5−CD10−CD27low phenotype, which compared to 
the adult had higher MFI of IgM (4,953 vs. 2,706; p = 0.057), an 
increased CD5 frequency (26.01 vs. 6.59%; p = 0.057) and MFI 
(202.5 vs. 39.88; p = 0.057), and a diminished frequency of CD27+ 
cells (0.92 vs. 5.34%; p = 0.1) (Figure 5; Table SIV and Figure S2 
in Supplementary Material).
hUcB Breg Present lower Membrane 
expression of cD22 than haPB Breg
In addition to the previously described markers, we studied 
others related to the activation and maturation state of B-cells. 
For each marker, we compared hUCB Breg cells with NoBreg 
cells and with their adult equivalents. For the activation status 
of Breg cells, we studied CD22, CD25, CD71, CD86, and PD-L1 
markers. In hUCB, we observed an increase in frequency and 
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FigUre 4 | Breg cells from hUcB inhibit iFn-γ and il-4 production by T-cells when cocultured. (a) Intracellular cytokine staining in one representative 
hUCB example of a T-cell-only culture with PIM stimulation. (B) hUCB Breg and NoBreg effect on T-cell SR (stimulated/basal) after 72 h coculture plus 5 h 
stimulation with PIM at 1:1 ratio (T-cells alone, T-cells:Breg, T-cells:NoBreg) in a CD3-coated plate (n = 6). SR, stimulation ratio; PIM, PMA and ionomycin in the 
presence of monensin; hAPB, human adult peripheral blood; hUCB, human umbilical cord blood; Breg, Regulatory B cells; NoBreg, non-regulatory B-cells. 
**p < 0.005.
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a decrease in MFI of CD25 in Breg cells when compared with 
NoBreg cells (4.37 vs. 2.78%; p = 0.03 and MFI: 7.46 vs. 54.33; 
p = 0.03). We observed no differences in CD71, CD22, CD86, 
and PD-L1 expression between hUCB Breg and NoBreg cells. 
Interestingly, there were differences between Breg from hUCB 
and hAPB: there was a decreased CD22 expression in hUCB 
(MFI: 800.9 vs. 1,293; p = 0.057) and a lower CD86 frequency 
(0.58 vs. 5.8%; p: 0.057). These differences did not reach statisti-
cal significance possibly due to the high variability observed in 
adults (Figure 5; Table SIV in Supplementary Material; Figure 
S2 in Supplementary Material). This variability may account for 
the different antigenic stimulations occurring during the lifes-
pan of a person and the divergence of this experience increasing 
over the years.
cD73 ectonucleotidase seems not to Be a 
Mechanism of regulation in hUcB
CD73 is an ectonucleotidase that produces adenosine-inhibiting 
T-cell responses in an IL-10-independent way that has been 
related with regulatory functions of B-cells (5). To explore the 
presence of an IL-10-independent suppression mechanism in 
hUCB, we studied CD73 expression in the membrane of Breg 
and NoBreg cells in both hUCB and hAPB. There was a lower 
CD73 expression frequency in Breg cells compared with NoBregs, 
in both hUCB (13.45 vs. 50.83%; p = 0.03) and hAPB (37.98 vs. 
85.7%; p = 0.1). Of note, the frequency observed in hUCB Breg 
was lower than hAPB (p =  0.057). This fact suggests that the 
IL-10-independent suppression by CD19+CD24hiCD38hi Breg 
cells is not related to CD73 expression (Figure 5; Table SIV in 
Supplementary Material; Figure S2 in Supplementary Material).
DiscUssiOn
This study presents the functional and phenotypical charac-
terization of the increased Breg cell subset in hUCB defined as 
CD19+CD24hiCD38hi cells. Bregs were present with greater fre-
quency in hUCB and were most markedly observed in marginal 
zone-like B-cells. At a functional level, hUCB B-cells (including 
both Breg and NoBreg) produced higher levels of IL-10 spon-
taneously. hUCB Bregs demonstrated their regulatory capacity 
by differentially inhibiting IFN-γ and IL-4 production by T-cells 
when cocultured. Phenotypically, hUCB Bregs presented a similar 
phenotype to that described in hAPB with an increased quantity 
of IgM per cell and a diminished frequency of CD27 and with 
less CD22 in their membrane. Finally, hUCB Bregs also presented 
lower expression levels of the IL-10-independent inhibitor CD73. 
To our knowledge, this is the second attempt to characterize the 
population of CD19+CD24hiCD38hi cells in human cord blood. 
The first attempt was recently reported (41), but the phenotype 
of hUCB Breg was not fully characterized.
A B
FigUre 5 | hUcB Breg cell-defining phenotype corresponds with that previously described for Bregs. (a) Frequency of known Breg cell markers and 
others among Breg and NoBreg cells. Y axis value corresponds to % of positive cells, and area of the circle corresponds to the MFI of the whole population.  
(B) Heatmap of % and MFI of the different T-cell markers in Bregs and NoBregs from hAPB (n = 3) and hUCB (n = 4), with green being the lowest values and red the 
highest. hUCB, human umbilical cord blood; hAPB, human adult peripheral blood; Breg, B regulatory cell; NoBreg, non-regulatory B-cell; MFI, mean fluorescence 
intensity. * and # denote MFI and frequency statically significant differences, respectively. */#p < 0.05, **/##p < 0.01, and ***/###p < 0.001.
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Healthy umbilical cord blood marginal zone-like B-cells 
presented the greatest difference in proportion of Breg cells 
when compared with adults. Circulating marginal zone B-cells 
are representative of splenic marginal zone B-cells, having 
a prediversified immunoglobulin repertoire and initiating 
T-cell-independent responses through TLRs as activation sig-
nals. Their responses are mainly directed against encapsulated 
bacteria, including commensal microbiota (49–51). Marginal 
zone B-cells also play a role in normal pregnancy development 
(52), and it is known that antiencapsulated bacteria responses 
are lower in infants and young children (36). As TLRs activate 
Bregs (2, 3), the greater proportion of marginal zone-like B-cells 
observed might indicate increased cooperation in regulatory 
function after encapsulated bacterial stimulation. Also, we 
observed lower  levels of CD22 in the membrane of hUCB Bregs, 
suggesting a lower activation threshold (32), which could be 
of importance in the rapid abrogation of unwanted responses 
to commensal bacteria. During the first contacts with the 
extrauterine environment and the adoption of microbiota, we 
might hypothesize the increased proportion of Breg cells among 
marginal zone B-cells to be one of the mechanisms by which 
the neonatal immune system protects itself from an exacerbated 
response to the new range of antigens it is exposed to.
We observed that all B-cells, Breg, and NoBreg, from hUCB 
spontaneously produced more IL-10 than their adult counter-
parts, but there were no significant differences between Breg 
and NoBreg hUCB cells. It has previously been observed that 
CD19+CD24hiCD38hi and CD19+CD24intCD38in T-cells from 
hUCB are capable of producing similar amounts of IL-10 after 
stimulation (41). Unlike other recently published studies (41), 
we observed a significant inhibition of IFN-γ production only 
when T-cells and Bregs were cocultured. We speculate that this 
discrepancy could be due to differences in the experimental 
design. We performed a coculture with either Breg or NoBreg 
with CD3+CD25− T-cells for 72 h in the presence of plate-bound 
CD3 and, following that, a restimulation for ICS. Sarvaria et al. 
cocultured CD4+ cells with either Breg or NoBreg cells, stimu-
lated them with anti-CD3/CD28 for 96 h, and then analyzed the 
concentration of inflammatory cytokines in the supernatant (41).
The mechanism by which hUCB Breg cells perform their 
regulatory function is unclear. We observed a differential regula-
tory activity of Breg and NoBreg cells spontaneously producing 
similar amounts of IL-10. It is known that Breg cells can carry 
out part of their functions via IL-10-independent mechanisms, 
such as IL-35 and TGF-β secretion and cell-to cell-contact (1, 6). 
Immune regulation by hUCB B-cells seems to be partially medi-
ated by (i) IL-10 production, as seen in IL-10-blockade experi-
ments and (ii) cell-to-cell direct contact (mediated by CD80/
CD86), but independently of TGF-β (41). The mechanisms by 
which hAPB Bregs perform their suppressive activity have been 
further studied (5–7, 53), but more investigation is needed to 
understand whether there are other mechanisms in hUCB Breg 
cell regulation of T-cells.
We observed an increased quantity of IgM per cell in hUCB 
Breg cells compared to NoBreg cells and hAPB Breg cells, which 
could have implications in the mechanism of action of these 
Breg cells. Naturally occurring IgM antileukocyte autoantibodies 
(IgM-ALA) are antibodies with suppressor capacity that can 
inhibit T-cell activation and chemotaxis (54, 55). IgM-ALA anti-
bodies are present at birth (55), and they inhibit pro-inflammatory 
cells from producing IFN-γ and IL-17 in response to alloantigens 
in mice (54). Altogether, we speculate that this could be a new 
Breg IL-10-independent mechanism for their regulatory func-
tion that could be of special importance during pregnancy and 
the postnatal period. More research should be done to evaluate 
whether these are true regulatory mechanisms of hUCB Breg 
function.
Healthy umbilical cord blood Breg cells presented diminished 
CD22 expression, suggesting a lower activation threshold. CD22 
modulates the BCR signal and prevents the hyperactivation of 
B-cells upon stimulation (32–34). CD22 knock-out mice pre-
sented increased circulating IgM and with more IL-10-competent 
T-cells (35) and Breg cells CD1dhiCD5+ (56) in the spleen. These 
B-cells have the capacity to inhibit the IgG response to non-self 
and self-antigens (35). Also, in vivo treatment of mice with anti-
CD22 mAb depletes spleen B10 and marginal zone cells in mice 
(57). We hypothesize that the lower level of CD22 in hUCB Breg 
is one of the explanations for the increased frequency of Breg 
among marginal zone-like B-cells. Although there is a Breg cell 
subset characterized by high expression of CD25 in the membrane 
of B-cells (53), we did observe a decrease in the presence of this 
receptor. CD25hi Bregs described by Kessel et al. also presented 
high levels of CD86 and CD27 (53), suggesting that these two 
Breg cell groups have a convergent function but are not the same 
subsets.
Regulatory B cell population can be of importance in the Th1/
Th2 bias observed in neonates (39). The neonate immune system 
has the enormous challenge of modulating the migration from the 
sterile uterus to the real world (36). During pregnancy, the fetus 
tolerates the mother’s allogenicity, dealing after birth with a huge 
range of antigens and microorganisms, pathogenic or not (36, 39). 
We hypothesized that, as CD5+ murine B-cells contribute to the 
reduced production of IL-12 by APCs (58), increased hUCB Breg 
contributes to the limited Th1 response observed in neonates 
inhibiting IFN-γ production. It has been observed that B-cells 
recovered from patients after stem cell transplantation without 
GvHD had increased levels of IL-10-producing B-cells, suggesting 
the inhibitory role of these cells (41). Also, CD24hiCD38hi B-cells 
have been studied during pregnancy, and it has been shown that 
they correlate with Treg cell numbers during pregnancy and 
that they increase postpartum (7, 12). There was an increase in 
transitional B-cells (IgMhiCD38hi) in asthmatic pregnant women 
whose progeny developed allergy signs before 6 months of age 
(20). It would be of interest to confirm whether these cells express 
high levels of CD24, thus producing one more clue to the role of 
Breg cells in the Th1/Th2 bias observed in neonates.
Availability of hUCB samples is the major limitation of our 
study. However, it should be mentioned that in spite of the small 
number of samples, the same findings were consistently found in 
each of the samples analyzed, which strengthens the results.
Finally, we show that Breg cells were not only present in hUCB 
but also present at an increased frequency compared with hAPB, 
especially among marginal zone-like B-cells, and that they have 
the capacity to produce more IL-10 already at baseline while 
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developing their regulatory function by inhibiting T-cell IFN-γ 
and IL-4 production, among others, thereby likely contributing 
to the limited Th1 response observed in neonates at delivery. The 
phenotypical differences observed between hUCB and hAPB 
Bregs lead us to construct hypotheses about the mechanisms 
of tolerance achievement in the fetus. Understanding of how 
immune tolerance to the newborn’s haploidentical mother and 
to harmless antigens is achieved is of the utmost importance to 
further advance knowledge and treatment of immune-related 
diseases in the fetus and the newborn. However, more investi-
gation with neonatal hUBC Breg cells is required to decipher 
their regulatory mechanisms and their role in special pregnancy 
conditions such as chronic autoimmune disease, HIV infection, 
and premature delivery.
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